Home / Health / New Obesity Drug Shatters Weight Loss Records
New Obesity Drug Shatters Weight Loss Records
11 Dec
Summary
- Retatrutide patients lost up to 71.2 pounds in 68 weeks.
- Drug significantly reduced knee arthritis pain by 75.8%.
- Cardiovascular risk biomarkers and blood pressure were lowered.
A groundbreaking obesity drug, retatrutide from Eli Lilly, has achieved record-breaking weight loss in clinical trials. Patients using the highest dose of this once-weekly injection lost an average of up to 71.2 pounds over 68 weeks, surpassing results from existing popular weight-loss medications.
Beyond its dramatic impact on weight, retatrutide offered significant relief for common co-occurring conditions. The drug reduced arthritic knee pain by an impressive 75.8% and notably improved participants' physical abilities, with some patients becoming completely pain-free.
Furthermore, retatrutide positively influenced cardiovascular health markers. It lowered systolic blood pressure by 14 millimeters of mercury and reduced other key biomarkers associated with cardiovascular risk, presenting a multifaceted therapeutic benefit.
